<div>
  <ul>
    <li>
      <p>
        Brazilian plant-based meat producer Fazenda Futuro (Future Farm), partnered with prepared meals company Dineamic to launch five new plant-based meal options.
      </p>
    </li>
    <li>
      <p>
        The new range includes pumpkin &amp; future mince bolognese with ravioli, harissa future meatballs with vegetable couscous, and future meatballs with creamy tomato sauce and casarecce. Further two dishes for the range have been created by Masterchef Australia 2021 winner and Future Farm ambassador Justin Narayan, they include future mince Sri Lankan curry with rice &amp; broccoli, and umami mushroom and future mince stir-fry with rice &amp; green beans.
      </p>
    </li>
    <li>
      <p>
        Consumers can purchase the Dineamic X Future Farm range at a price of AUD 11.50 (~USD 7.50) from Woolworths, Coles, and IGA stores. This product range is ~248% more expensive than the value frozen meal range at Woolworths supermarkets.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://insidefmcg.com.au/2022/11/08/dineamic-rolls-out-five-plant-based-meals-in-future-farm-collab/">
      Inside FMCG
    </a>
  </p>
</div>


Plant-based Meat

Future Farms partners with Dineamic to launch plant-based meals

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>A UK-based psychedelic company, Compass Pathways, and Journey Clinical, a psychotherapy platform, have formed a research collaboration. Their aim is to investigate the deployment and health provider training for COMP360 psilocybin treatment for treatment-resistant depression (TRD), which is currently being reviewed by the FDA.</p>
 <p>The collaboration will involve sharing information about the delivery model of the COMP360 program. If the FDA approves COMP360 for TRD, the partners will further analyze patient experiences, reimbursement processes, innovative care pathways. They will also examine therapist training and treatment settings.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> As Compass Pathways nears FDA approval for its psilocybin program, it is actively partnering with others to support its product development initiatives. In January 2024, it partnered with <a href="https:<br>
//sp-edge.com/updates/25618"> Hackensack Meridian Health </a> to support research efforts using psilocybin in mental health treatments. Also, during the same month, it partnered with <a href="https:<br>
//sp-edge.com/updates/25237"> Greenbrook TMS </a> to explore delivery models for the COMP360 program.</p>

Compass Pathways and Journey Clinical collaborate to develop deployment and training model for COMP360 psilocybin treatment

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 <p>Deciphera Pharmaceuticals has signed a definitive merger agreement with ONO Pharmaceutical. The deal entails ONO purchasing all remaining normal shares of Deciphera for a total sum of about USD 2.4 billion, at a rate of USD 25.60 per share.</p>
 <p>The merger plans to reinforce ONO Pharmaceutical's pipeline and accelerate its worldwide expansion initiatives by utilizing Deciphera's proficiency in kinase inhibition and its commercialization platform in key markets.</p>
 <p>Hailing from Japan, Ono Pharmaceutical is a firm specializing in prescription pharmaceuticals and diagnostic reagents. It partakes in research and development, production, and sales of medications and health products. The company’s product range encompasses treatments for illnesses such as cancer, type II diabetes, overactive bladder, osteoporosis, Alzheimer's disease, and multiple respiratory disorders.</p>
 
</div>

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for USD 2.4 billion to expand oncology portfolio

<div>
 <p>MiLaboratories and Miltenyi Biotec have announced a partnership that will integrate MiLaboratories' RNA kit technology for immune sequencing with Miltenyi Biotec's production and marketing capacity, aiming to promote the development and application of next-generation treatments. MiLaboratories will offer its immune sequencing technology, through RNA kits, to Miltenyi Biotec for widespread distribution, backed by Miltenyi Biotec's global reach.</p>
 <p>The partnership involves Miltenyi Biotec incorporating MiLaboratories’ software solutions - MiXCR and Platforma - into its product line to enhance research functionality and efficiency. The collaboration is expected to drive innovation and the development in genomics, supplying advanced tools to worldwide researchers and medical professionals. </p>
 <p>Primarily, MiLaboratories is a biotech company renowned for devising proprietary software aimed at capturing and comprehending the human immune system on a DNA level. The company's landmark product, MiXCR, is a software toolkit used for analyzing immunological sequencing data.</p>
</div>

MiLaboratories partners with Miltenyi Biotec to advance next-generation therapies

<div>
 <p>X4 Pharmaceuticals has obtained approval from the US FDA for their product, XOLREMDI (mavorixafor). This medication is designed for patients aged 12 and over who are suffering from WHIM syndrome. This condition is characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. XOLREMDI aims to increase the presence of mature neutrophils and lymphocytes in their circulation.</p>
 <p>XOLREMDI operates by inhibiting the CXC chemokine receptor 4 (CXCR4). This is the first treatment specifically designed for those with WHIM syndrome, a disease that combines primary immunodeficiency and chronic neutropenia. These health issues occur due to abnormalities in the CXCR4 pathway.</p>
 
</div>

X4 Pharmaceuticals receives US FDA approval for XOLREMDI for WHIM syndrome

<div>
 <p>Health Tech company GenomOncology has enhanced its software platform, GO Pathology Workbench, used for in-depth analysis and reporting of results from next-generation sequencing (NGS) and other molecular tests. The improvements incorporate expanded support for germline testing, amplifying its analytical reach across all assays, including tumor sequencing, hereditary cancer, and rare diseases.</p>
 <p>The upgraded GO Pathology Workbench includes the FDA-acknowledged ClinGen database for additional germline testing and offers full backing for the American College of Medical Genetics (ACMG) classification system. It also features a new workflow choice and extra functionalities for comprehensive exome and genome sequencing analysis, which permits cross-platform tertiary analysis and reporting.</p>
 <p>GenomOncology specializes in designing precision oncology software solutions. It employs its Precision Oncology Platform (POP) that uses pioneering algorithms and ML to convert genomic data into actionable discoveries for cancer treatment​. The platform also utilizes the igniteIQ and GOConnect data enablement solutions to process raw, unstructured data into valuable insights. Also, its GO Pathology Workbench solution enables molecular pathology labs to process genetic test results into actionable details and reports for clinician review.</p> 
</div>

GenomOncology launches upgraded version of GO Pathology Workbench software platform

Retail investors demanding sophisticated passive investment strategies are looking for an edge.

Retail Trading Infrastructure

TD Ameritrade fined USD 600,000 by FINRA over inconsistent automated approval system

Platforms, apps, and cards to keep the corporate wallet in check

Business Expense Management

INCUMBENTS_PRESENT

<div>
 <p>Ascend Software has collaborated with Pagero, a provider of e-invoicing solutions. The partnership will enhance invoice processing automation and compliance for users of Workday Financial Management.</p>
 <p>They plan to automate nearly 80% of supplier invoices, thus reducing manual data entry, by integrating these services into the existing financial infrastructure. This partnership emphasizes on global compliance and complete automation of the invoice process.</p>
 <p>Pagero, based in Norway, operates a Smart Business Network that facilitates the secure exchange of business documents like orders, invoices, and payment instructions. It aims to optimize order-to-cash and purchase-to-pay processes, leveraging significant and reliable data, regardless of location, industry, size, or pre-existing systems. This is achieved through its open network and associated value-added applications.</p>
</div> <p><b>Analyst QuickTake</b> :<br>
 The partnership follows Ascend Software’s launch of <a href="https:<br>
//sp-edge.com/updates/28428"> Ascend Payments </a> , where it is likely to leverage the new solution to automate payments for supplier invoices.</p>

Ascend Software partners with Pagero to automate global invoice processing and compliance

<div>
 
 <p>Accounts payable and receivable automation platform, Paymerang, has formed a partnership with M3 Accounting Solutions. The aim of this partnership is to incorporate Paymerang's payment automation technology into M3 Accounting Core's customer offerings.</p>
 <p>Post partnership, Paymerang's AP automation solutions will be combined with M3 Accounting Core solution via an API. This will allow hotel finance teams to instigate electronic payments to vendors directly. The automation process is expected to reduce manual tasks and lessen potential fraud risks related to check issuance.</p>
 <p>This feature is predicted to provide immediate access to financial data to hotel operators and enhance overall efficiency.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> The new partnership results from M3’s restructured strategic alliance program, which aims to strengthen its integrations with AP automation solutions.&nbsp;This also follows on the <a href="https:<br>
//sp-edge.com/updates/28896"> recent partnership </a> M3 announced with AvidXchange to provide M3 customers access to AvidXchange payment automation technology.&nbsp;</p>

Paymerang partners with M3 to streamline accounting processes for hoteliers

Clean, congestion-free air travel gets liftoff

Passenger eVTOL Aircraft

<div>
 
 <p>EHang Holdings Limited, an autonomous aerial vehicle technology company, has collaborated with Greater Bay Technology Co., Ltd. (GBT) to develop the first ultra-fast charging and extreme-fast-charging battery solutions for EHang's eVTOL aircraft.</p>
 <p>The partnership between EHang and GBT will lead to the development of advanced power system components for the eVTOL aircraft industry. The fast-charging technology will enable the aircraft's batteries to charge from 30% to 80% within 5–10 minutes, improving the performance, stability, and operational efficiency of eVTOL aircraft.</p>
 
</div>

EHang Holdings partners with Greater Bay Technology to develop ultra-fast-charging for eVTOL aircraft

<div>
 
 <p>EHang Holdings Limited, an autonomous aerial vehicle technology company, has collaborated with Multi-Level Group (MLG) and the Abu Dhabi Investment Office (ADIO) to further the development and implementation of electric vertical take-off and landing vehicles (eVTOLs) in the United Arab Emirates (UAE).</p>
 <p>This partnership is expected to lead to the establishment of a regional hub in Abu Dhabi. The hub will focus on manufacturing, flight operations, and research and development relating to eVTOLs. The goal is to revolutionize goods and passenger transportation using eVTOL technology.</p>
 
</div>

All Updates